Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 35 pages report, published by Global Markets Direct

Keywords : Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Therapeutics, Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Pipeline Overview, Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Pipeline, Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Pipeline Assessment

Report ThumbnailJune-2017
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2017

Summary

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 1 - Pipeline Review, H1 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Metabotropic glutamate receptor 1 (mGluR1) is a protein encoded by GRM1. It activates a phosphatidylinositol-calcium second messenger system. It participates in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Genetic Disorders which include indications Attention Deficit Hyperactivity Disorder (ADHD), Autism, Depression, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Melanoma, Schizophrenia and Status Epilepticus.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)
- The report reviews Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administrations, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Aevi Genomic Medicine Inc, H1 2017
  • Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2017
  • Dormant Projects, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Overview
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Companies Involved in Therapeutics Development
  • Aevi Genomic Medicine Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Drug Profiles
  • fasoracetam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FC-311 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JBPOS-0101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize mGlu1 for Schizophrenia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize GRM1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize mGluR1 for Depression - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-0467558 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Dormant Products
  • Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  • Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  • Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
  • Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
  • Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
  • Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
  • Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectMetabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2017Product ThumbnailMetabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2017, Industry ReportProduct #: 829002
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved